Royalty Pharma (RPRX) Goodwill & Intangibles (2019 - 2026)
Royalty Pharma's (RPRX) quarterly Goodwill & Intangibles came in at $924.6 million in Q1 2026, little changed quarter-over-quarter from $924.6 million in Q4 2025.
Royalty Pharma (RPRX) Goodwill & Intangibles (2019 - 2026) Analysis & Trends
Royalty Pharma has disclosed Goodwill & Intangibles across 5 years of filings, most recently posting $924.6 million for Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $924.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $924.6 million (changed N/A YoY), and the FY2025 annual result was $924.6 million, changed N/A from the prior year.
- Goodwill & Intangibles came in at $924.6 million for Q1 2026 at Royalty Pharma, roughly flat from $924.6 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $924.6 million in Q2 2025 to a low of $924.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Royalty Pharma | 23.13 Bn | 25.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 924.63 Mn |
| Dec 31, 2025 | 924.63 Mn |
| Sep 30, 2025 | 924.63 Mn |
| Jun 30, 2025 | 924.63 Mn |
| Dec 31, 2021 | 5.67 Mn |
| Sep 30, 2021 | 11.47 Mn |
| Jun 30, 2021 | 17.26 Mn |
| Mar 31, 2021 | 23.00 Mn |
| Dec 31, 2020 | 28.67 Mn |
| Sep 30, 2020 | 34.46 Mn |
| Jun 30, 2020 | 40.26 Mn |
| Dec 31, 2019 | 51.72 Mn |